scholarly article | Q13442814 |
P2093 | author name string | Sidney Croul | |
Donya Aref | |||
P2860 | cites work | Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome | Q24336457 |
Dissecting the genomic complexity underlying medulloblastoma | Q24621907 | ||
Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system | Q28270384 | ||
Subgroup-specific structural variation across 1,000 medulloblastoma genomes | Q28271811 | ||
beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee | Q28279527 | ||
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma | Q28284093 | ||
ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration | Q28284396 | ||
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 | ||
Subtypes of medulloblastoma have distinct developmental origins | Q28300616 | ||
Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog | Q28586621 | ||
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations | Q30040534 | ||
Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma | Q30156001 | ||
SPARC mediates Src-induced disruption of actin cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42 | Q30423594 | ||
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. | Q30447832 | ||
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features | Q33366431 | ||
Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. | Q33539849 | ||
Mutations in SUFU predispose to medulloblastoma | Q34133729 | ||
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. | Q34285237 | ||
Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma | Q34398276 | ||
The molecular basis of Turcot's syndrome | Q34662365 | ||
Rapid diagnosis of medulloblastoma molecular subgroups | Q34764793 | ||
Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma | Q43667669 | ||
N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. | Q45118490 | ||
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial | Q45120061 | ||
The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone | Q45121434 | ||
Treatment of early childhood medulloblastoma by postoperative chemotherapy alone | Q46367739 | ||
Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression | Q46507354 | ||
Molecular analysis of the lissencephaly gene 1 (LIS-1) in medulloblastomas | Q48063530 | ||
Structural chromosomal abnormalities in human medulloblastoma | Q48125276 | ||
Chromosome abnormalities in pediatric brain tumors | Q48135652 | ||
Large-cell medulloblastomas. A distinct variant with highly aggressive behavior | Q48459892 | ||
Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features | Q48805693 | ||
High-resolution deletion mapping of chromosome arm 17p in childhood primitive neuroectodermal tumors reveals a common chromosomal disruption within the Smith-Magenis region, an unstable region in chromosome band 17p11.2. | Q48822376 | ||
Epidemiology of adult medulloblastoma | Q50638609 | ||
Medulloblastoma. A report of 201 cases with emphasis on the relationship of histologic variants to survival | Q51120057 | ||
Role of Wnt pathway in medulloblastoma oncogenesis. | Q52547248 | ||
MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. | Q53201641 | ||
Stratification of medulloblastoma on the basis of histopathological grading. | Q53255752 | ||
Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. | Q53286039 | ||
Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. | Q53300055 | ||
An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. | Q54427712 | ||
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. | Q55468802 | ||
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. | Q55469539 | ||
Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. | Q55473840 | ||
"Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. | Q55474949 | ||
Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. | Q55476488 | ||
Sporadic medulloblastomas contain oncogenic beta-catenin mutations. | Q55477948 | ||
Correlation between polysialic-neural cell adhesion molecule levels in CSF and medulloblastoma outcomes. | Q55479479 | ||
Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. | Q55480515 | ||
Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute. | Q55481382 | ||
Medulloblastoma: survey of factors possibly influencing the prognosis. | Q55489984 | ||
Nuclear localization and mutation of beta-catenin in medulloblastomas | Q73662960 | ||
Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features | Q34866372 | ||
Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes | Q34977375 | ||
Anaplasia and grading in medulloblastomas. | Q35208292 | ||
APC mutations in sporadic medulloblastomas | Q35745470 | ||
Clonal selection drives genetic divergence of metastatic medulloblastoma | Q35784926 | ||
Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas | Q35796194 | ||
Novel mutations target distinct subgroups of medulloblastoma. | Q36143877 | ||
Morphing into cancer: the role of developmental signaling pathways in brain tumor formation | Q36205991 | ||
Functional genomics identifies drivers of medulloblastoma dissemination | Q36296016 | ||
Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions | Q36451030 | ||
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups | Q36460209 | ||
Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours | Q36620330 | ||
Medulloblastoma comprises four distinct molecular variants | Q36920479 | ||
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma | Q37002410 | ||
An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). | Q37177897 | ||
Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma | Q38340521 | ||
The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastoma. | Q38352855 | ||
ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. | Q38358939 | ||
MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group | Q38456964 | ||
Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma | Q39382947 | ||
MicroRNA-21 suppression impedes medulloblastoma cell migration | Q39503647 | ||
Calmodulin-kinases regulate basal and estrogen stimulated medulloblastoma migration via Rac1. | Q39627627 | ||
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis | Q39828521 | ||
c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. | Q39862140 | ||
The flavonols quercetin, kaempferol, and myricetin inhibit hepatocyte growth factor-induced medulloblastoma cell migration. | Q39879515 | ||
The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells | Q39904552 | ||
An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma | Q39910333 | ||
Integrins mediate adhesion of medulloblastoma cells to tenascin and activate pathways associated with survival and proliferation | Q39939384 | ||
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations | Q40339027 | ||
Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease | Q40781851 | ||
Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors | Q40795419 | ||
Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome | Q40851117 | ||
Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours | Q41099186 | ||
Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management | Q41449272 | ||
Genetics of pediatric central nervous system tumors | Q41667932 | ||
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 | Q42031842 | ||
Sporadic medulloblastomas contain PTCH mutations. | Q42434884 | ||
Basal cell carcinomas in mice overexpressing sonic hedgehog | Q42437252 | ||
Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. | Q42439709 | ||
Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. | Q42440473 | ||
A frequent activated smoothened mutation in sporadic basal cell carcinomas | Q42467910 | ||
P433 | issue | 4 | |
P921 | main subject | medulloblastoma | Q1333608 |
P304 | page(s) | 377-385 | |
P577 | publication date | 2013-07-01 | |
P1433 | published in | CNS oncology | Q26842350 |
P1476 | title | Medulloblastoma: recurrence and metastasis | |
P478 | volume | 2 |